Form 4 for CLRB Cellectar Biosciences, Inc.
Accepted 2025-07-03 00:00:00 ET · period of report 2025-07-02 · accession 0001104659-25-065573 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-03 | 2025-07-02 | CLRB | CARUSO JAMES V | CEO, Dir | P - Purchase | $4.99 | +10.0K | 11.6K | +611% | +$49.9K |
| D | 2025-07-03 | 2025-07-02 | CLRB | CARUSO JAMES V | CEO, Dir | P - Purchase | $0.01 | +10.0K | 10.0K | New | +$100 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-02 | P | A | 10,000 | $4.99 | 11,638 | D | — | — | (F1) This number has been adjusted for the one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025. |
| 2 | Derivative | Warrants | 2025-07-02 | P | A | 10,000 | $0.01 | 10,000 | D | $5.25 · 2025-07-02 to 2030-07-02 | 10,000 Common Stock |